Physician profile
Samuel Sim
NPI 1275633844
$12,967.89
in general payments reported to CMS, 2019-2025
36 companies · $532 in 2025
The $532 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,759 · 2020: $1,126 · 2021: $2,208 · 2022: $3,234 · 2023: $2,531 · 2024: $578 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,565 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.86 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,198.38 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,389.24 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,176.59 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $925.60 | 2019-2023 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $792.21 | 2020-2023 | |
| Celgene Corporation | $772.85 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $475.97 | 2019-2023 | Ocaliva |
| Pfizer INC. | $470.47 | 2019-2024 | |
| Daiichi Sankyo INC. | $392.71 | 2019-2023 | Injectafer |
| Gilead Sciences, INC. | $369.61 | 2019-2021 | |
| Boston Scientific Corporation | $344.34 | 2019-2022 | |
| Novo Nordisk INC | $319.61 | 2025 | Wegovy |
| Lilly USA, LLC | $266.19 | 2024-2025 | Omvoh, Zepbound |
| Braintree Laboratories, INC. | $233.60 | 2019-2023 | Sutab |
| Genzyme Corporation | $202.97 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $202.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $184.51 | 2022-2023 | Zeposia |
| Shionogi INC | $178.84 | 2019 | |
| Janssen Scientific Affairs, LLC | $153.30 | 2021-2022 | |
| Madrigal Pharmaceuticals | $153.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $143.45 | 2019-2022 | |
| Ucb, INC. | $105.57 | 2019-2023 | Cimzia |
| Ferring Pharmaceuticals INC. | $76.35 | 2019 | |
| Aimmune Therapeutics, INC. | $74.03 | 2023 | |
| Amgen INC. | $63.91 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $49.13 | 2022-2023 | Dupixent |
| Allergan, INC. | $47.28 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $36.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.30 | 2024 | |
| Qol Medical, LLC | $26.04 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.02 | 2025 | Iqirvo |
| Exact Sciences Corporation | $20.56 | 2023 | Cologuard Collection Kit |
| Apollo Endosurgery US INC | $19.69 | 2019 | |
| Pentax of America, INC. | $18.43 | 2020 | |
| Romark Laboratories, Lc | $18.21 | 2019 | |
| Fresenius Kabi USA, LLC | $14.15 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Sim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.